SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected fourth-quarter outlook, amid PC weakness and supply constraints, overshadowed a stronger third-quarter report and drove a sharp selloff. Traders largely criticized the guidance and execution, while some called the drop an overreaction and viewed the shares as oversold.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks strong quarterly results and upbeat outlook, supported by booming AI data-center NAND demand, are drawing attention alongside its announced 8-for-1 stock split. Traders are debating the sharp, volatile selloff despite the positive report, attributing it variously to profit-taking and a broader tech-sector risk-off move, while others question whether growth and memory pricing can remain sustainable.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook sparked a selloff, as investors focused on slight misses against expectations, softer forward guidance, and heavy AI infrastructure spending that is weighing on cash flow. Traders are split: bears see spending and cash-flow risks, while bulls point to strong AWS growth and view the drop as an overreaction.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are under pressure after a strong Q3 earnings beat was overshadowed by weaker-than-expected Q4 revenue guidance, slowing user growth and a decline in U.S. daily active users, alongside concerns about falling Google search referrals. Traders debate whether the selloff is excessive given revenue growth and profitability, while others worry that a planned login requirement could further limit traffic and monetization.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Mega-cap tech weakness and earnings reactions are weighing on QQQ, with traders pointing to Googles selloff, Intels weak outlook, and Amazons results. The dominant debate is whether heavy AI spending is failing to show sufficient returns and signaling a broader tech unwind, or whether the pullback is a buying opportunity amid sector rotation.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated lifileucel lung-cancer trial results sparked a sharp selloff: the overall response rate remained around one in four, while a small, retrospectively identified biomarker subgroup showed a much higher response rate. Traders are divided over whether the subgroup points to a promising precision-treatment path or signals a narrower opportunity and greater uncertainty about durability, FDA approval timing, and managements presentation of the data.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians better-than-expected third-quarter results and raised delivery outlook have put the R2 production ramp in focus. Bulls see improving execution, while skeptics point to continued losses and cash burn; speculation about a Walmart van deal remains unconfirmed.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins choppy consolidation and repeated rejection near resistance dominate the discussion, with traders watching whether support holds. The community is split between expecting a deeper downturn and viewing pullbacks as accumulation ahead of a breakout, amid uncertainty around Fed policy and broader market weakness.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broader semiconductor pullback as traders react to Samsungs profit miss and Microsoft and Alphabet spending less on capital expenditures than expected, raising concerns about AI infrastructure demand. The community is split between seeing the decline as sector-driven pressure and expecting further downside, while bulls argue AMDs data-center and AI-chip prospects remain intact.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategys quarterly results have sparked debate: bulls point to the reported earnings beat, while skeptics argue it was driven by Bitcoin gains and focus on the revenue miss and financing costs. Bitcoins selloff and concerns about dilution and preferred-share dividends are adding pressure, with traders divided over whether the drop is a buying opportunity or a sign of further downside.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly Milestone and Triple-Digit Growth Outlook Put This Microcap in Focus

The pharmaceutical industry loses billions each year on drug candidates that perform well in animal testing but ultimately fail in human trials, most often because of safety concerns. As regulators push for more predictive human-based testing models, companies developing next-generation preclinical technologies are beginning to attract growing attention from both pharmaceutical partners and investors.Shares of VivoSim Labs, Inc. (Nasdaq: VIVS) are climbing Wednesday after the company announced it received a $5 million milestone payment from Eli Lilly while also issuing fiscal 2027 guidance ...

Why Vivosim Labs Shares Are Rocketing on Wednesday?

VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.read more...

Wall Street Turning Towards Momentum Narratives

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR

VivoSim Lands $5M from Eli Lilly as FDA's Animal-Testing Shift Fuels Projected 500%+ Revenue Explosion

VivoSim Labs (NASDAQ:VIVS) delivered two developments that could significantly strengthen its investment narrative: a $5 million milestone payment from Eli Lilly tied to a previously divested inflammatory bowel disease drug program, and guidance calling for more than 500% revenue growth in fiscal 2027 as demand accelerates for its human-based preclinical testing platform.

Top Biotech Stocks To Follow Today - February 1st

Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...

Biotech Stocks To Keep An Eye On - January 31st

Biotech Stocks To Follow Today - January 30th

Danaher, VivoSim Labs, Moderna, Vaxcyte, and Dianthus Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

Why Is VIVS Stock Up 79% Today?

Equity

VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.


VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

VivoSim Labs Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>NAMKind human-based toxicology services is designed to help drug developers identify liver and gastrointestinal liabilities earlier in the development process.&nbsp;</li><li>The company also said that it is continuing to scale capacity to support expanding global demand.</li><li>The company also anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration announcement last year that sought to reduce animal testing requirements.</li></ul>Shares of VivoSim Labs, Inc. (VIVS) rose about 79% on Friday after the company announced expansion into Korea and China for its NAMKind toxicology services.VivoSims <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229075/0/en/VivoSim-Expands-Asia-Pacific-Access-to-NAMKind-Human-Based-Toxicology-Services-Through-New-Distributor-Agreement-in-Korea-and-China.html">said</a> on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for NAMKind.<h2 class="st-heading-2">Expansion Details</h2>VivoSim Labs provides new approach methodologies for preclinical safety and NAMKind human-based toxicology services is designed to help drug developers identify liver and gastrointestinal liabilities earlier in the development process, helping avoid downstream failures.It also helps prioritize the right assets at the onset for pharmaceutical and biotechnology organizations.VivoSim said the new distributors will allow it to expand the company’s commercial presence across the Asia-Pacific.The company also said that it is continuing to scale capacity to support expanding global demand as drug developers seek earlier readouts, clearer translation to clinical outcomes, and meaningful reductions in late-stage attrition.The company also anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration announcement last year that sought to reduce animal testing requirements in favor of non-animal methods. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VIVS stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.“Not a bad session at all for momentum traders,” a Stocktwits user said. “Price moved cleanly higher. Buyers stayed in control.”<stembedurl>https://www.stocktwits.com/topstockalerts/message/643480801</stembedurl>Another user said they see a further rally up to $4.50.<stembedurl>https://www.stocktwits.com/MoeMoe66/message/643463733</stembedurl><a href="https://stocktwits.com/symbol/VIVS">VIVS stock</a> has lost about 27% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cort-shares-plummer-on-fda-drug-rejection-letter-reveal/cmySqTUR4SV">CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.

VivoSim Labs, Inc.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.1577
Prev Close	$0.1457
Open	$0.1471
Dividend Yield	0.00%
50-Day Moving Average	$0.228
Beta	0.71
Avg. Volume	933,174.29
PE Ratio	-0.03

52-Week High	$3.40
52-Week Low	$0.1417
Market Capitalization	$2.42M
EPS (Annual)	-$5.35
Price to Book	-0.20
Revenue Per Employee	$8,733.33

Feed

News

Sentiment

Fundamentals

Info

VIVS Fundamentals